Skip to main content
TipRanks
Go Ultimate75% OFF

Cutia Therapeutics (2487) Stock Price & Analysis

2 Followers

2487 Stock Chart & Stats

HK$0.66HK$0.01(1.54%)
At close: 4:00 PM GMT+8
HK$1HK$1.5HK$2Aug 24Sep 7Sep 21Oct 5Oct 20Nov 2Nov 16
Day’s Range
HKD 0.64 - HKD 0.67
52-Week Range
HKD 0.60 - HKD 7.10
Previous Close
HKD 0.65
Volume
N/A
Average Volume (3M)
577.13K
Market Cap
HKD 248.55M
Enterprise Value
HKD 621.20M
Total Cash (Recent Filing)
HKD 626.38M
Total Debt (Recent Filing)
HKD 274.17M
Price to Earnings (P/E)
―
Beta
1.30
Next Earnings
Mar 30, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth And Gross Margin

Revenue growth rebounded to 30.8% in 2025 after about 1.0% in 2024, while gross margin held at roughly 45.7%. This combination indicates stronger commercial traction with meaningful gross profit retained, creating a base for future operating leverage if investment intensity moderates.

Manageable Leverage

Debt-to-equity of about 0.36 remained similar to 2024, while equity stayed positive at about 885.7M in 2025. Manageable leverage and a substantial equity cushion provide more flexibility to fund operations than a highly debt-dependent structure, although losses remain a constraint.

Improving Cash Burn

Operating cash flow improved from approximately -443.0M in 2024 to -290.1M in 2025, and free cash flow improved from -468.7M to -303.0M. The narrower burn suggests better cost control or working-capital dynamics, which could extend financial flexibility while the company pursues growth.

Bears Say

Severe Unprofitability

2025 operating margin was approximately -89.3% and net margin approximately -101.2%, showing losses remain exceptionally large relative to revenue. Persistent unprofitability limits internally generated funding, increases dependence on financing, and makes the path to sustainable earnings uncertain over the next several quarters.

Ongoing Negative Cash Flow

Operating cash flow of roughly -290.1M and free cash flow of roughly -303.0M remained negative in 2025. Continued cash consumption means the business has not yet funded operations organically and still relies on external funding, potentially constraining investment choices if losses persist.

Declining Equity Base

Equity declined from about 974.7M in 2024 to 885.7M in 2025, while return on equity was approximately -37.4%. This erosion indicates that ongoing losses are reducing the balance-sheet cushion and could weaken resilience or financing capacity if the pattern continues.

Cutia Therapeutics News

2487 FAQ

What was Cutia Therapeutics’s price range in the past 12 months?
Cutia Therapeutics lowest stock price was HK$0.60 and its highest was HK$7.10 in the past 12 months.
What is Cutia Therapeutics’s market cap?
Cutia Therapeutics’s market cap is HK$248.55M.
When is Cutia Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Cutia Therapeutics’s earnings last quarter?
Cutia Therapeutics released its earnings results on Aug 31, 2026. The company reported -HK$0.584 earnings per share for the quarter.
Is Cutia Therapeutics overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Cutia Therapeutics pay dividends?
Cutia Therapeutics does not currently pay dividends.
What is Cutia Therapeutics’s EPS estimate?
Cutia Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cutia Therapeutics have?
Cutia Therapeutics has 376,583,700 shares outstanding.
What happened to Cutia Therapeutics’s price movement after its last earnings report?
Cutia Therapeutics reported an EPS of -HK$0.584 in its last earnings report. Following the earnings report the stock price went down -2.302%.
Which hedge fund is a major shareholder of Cutia Therapeutics?
Currently, no hedge funds are holding shares in HK:2487
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology